In the news release, NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting, issued 04-Mar-2009 by NewCardio, Inc. over PR Newswire, we are advised by the company that there was an error in the second paragraph of the press release. The complete, corrected release follows:
NewCardio Leadership to Present Clinical Data of Fully Automated QTinno(TM) Study at American College of Cardiology Annual Meeting
Data have also been accepted for publication as an original article by the peer-reviewed Journal of Electrocardiology
SANTA CLARA, Calif., March 4 /PRNewswire-FirstCall/ -- NewCardio, Inc. a cardiac diagnostic and services company, today announced that Dr. Ihor Gussak, NewCardio’s Vice President and Chief Medical Officer, will present at the American College of Cardiology (ACC) 58th Annual Scientific Session in Orlando on March 29, 2009.
Dr. Gussak, on behalf of Drs. Branislav Vajdic (NewCardio’s Chief Executive Officer), Samuel George (Senior Consultant to NewCardio), Ljupco Hadzievski, Steven F. Francom, and Peter Kowey (a member of NewCardio’s Scientific Advisory Board), will present “Comparison of QTinno, a Fully Automated ECG Analysis Program, to Semi-Automated Methods in Analysis of ECGs From a Drug Safety Study.” Also, a full-size, original article on QTinno performance has been accepted for publication by The Journal of Electrocardiology.
The conference features the latest and most innovative findings in cardiovascular science, as well as the most clinically relevant practical applications. More information on this conference is available at http://acc09.acc.org/Pages/default.aspx online.
Dr. Gussak commented, “The presented data demonstrates outstanding accuracy, reproducibility, and consistency of our 3-dimensional platform technology in the key electrocardiographic interval measurements, which enables the fully automated reading of ECGs in drug safety and Thorough QT studies. Unlike manual, semi-automated, and other 2-dimensional technologies and approaches, NewCardio’s proprietary 3-dimensional platform technology not only matches the most rigorous manual readings from some of the world’s most highly trained cardiologists in a fully automated manner, but also demonstrates very low variability of the results. Unlike these 2-D approaches, QTinno can extract previously unavailable diagnostic data, utilizing all data to obtain a 3-dimensional view of the cardiac activity. It does this without changing any of the standard practices of ECG collection.”
Dr. Vajdic added, “In an increasingly challenging clinical research and drug development environment, pharmaceutical companies continue to look for ways to increase efficiency, accelerate drug development, and reduce the costs of drug development, and Contract Research Organizations seek competitive advantages to maintain profit margins and capture market share. NewCardio’s proven ability to process electrocardiographic results with unrivaled accuracy in a fully automated fashion provides the ideal solution for these industry-wide challenges. We look forward to sharing the results of this study at this and other prestigious conferences, as well as in peer-reviewed journals.”
About NewCardio, Inc.
NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio’s development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio’s three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.
To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0
CONTACT: investors, Jeff Stanlis, Partner and Vice President of
Communications of Hayden IR, +1-602-476-1821, jeff@haydenir.com, for
NewCardio, Inc.
Web site: http://www.newcardio.com/
